Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 72

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 72
---
 and such changes may cause short-term billing errors that may take significant
time to resolve. If claims are not submitted to payors on a timely basis or are erroneously submitted, or if PPLS is required to switch
to a different provider to handle claim submissions, it may experience delays in its ability to process these claims and receipt of payments
from payors, or possibly denial of claims for lack of timely submission, which would have an adverse effect on its, and therefore our,
revenue and business.

Risks
Related to Intellectual Property Rights

Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.

The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

    ●
    others
    may be able to make diagnostic tests and therapeutic product candidates that are the same as or similar to ours but that are not
    covered by the claims of the patents that we own or have exclusively licensed;

    ●
    we
    or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending
    patent application that we own or have exclusively licensed;

    ●
    we
    or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;

    ●
    others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;

    ●
    it
    is possible that noncompliance with the U.S. Patent and Trademark Office (“USPTO”) and foreign governmental patent agencies
    requirement for a number of procedural, documentary, fee payment, and other provisions during the patent process can result in abandonment
    or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;

    ●
    it
    is possible that our pending patent applications will not lead to issued patents;

 37 

    ●
    issued
    patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal
    challenges by our competitors;

    ●
    our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive tests and products for sale in our